Context Therapeutics (CNTX) Stock Price
Context Therapeutics Price
Context Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Context Therapeutics business model & stock analysis
Frequently asked questions about Context Therapeutics
16 analysts currently rate the Context Therapeutics stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Context Therapeutics to generate revenue of 2.00 M USD and earnings per share of -0.48 USD.
Converted at the current exchange rate, the Context Therapeutics share trades at 0.17 EUR (0.19 USD).
The Context Therapeutics share (CNTX) is listed on 3 stock exchanges, including: NASDAQ (CNTX), Frankfurt (6K9.F), München (6K9.MU).
The expected revenue of Context Therapeutics is 2.00 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Context Therapeutics is -43.89 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Context Therapeutics is currently -0.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Context Therapeutics stock.
The price-to-sales ratio (P/S) of Context Therapeutics is currently 8.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Context Therapeutics stock.
The Eulerpool Quality Score for Context Therapeutics is 3/10.
The ISIN of Context Therapeutics is US21077P1084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Context Therapeutics is A3CWBU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Context Therapeutics is CNTX. The ticker symbol is used to trade Context Therapeutics shares on the stock exchange.
Context Therapeutics stock
Context Therapeutics Peer Group
Context Therapeutics Ticker
Context Therapeutics FIGI
All fundamentals and in-depth analysis of Context Therapeutics
Our stock analysis for Context Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Context Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.